Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz Sells 6,500 Shares

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Voyager Therapeutics Price Performance

VYGR traded up $0.13 during trading on Thursday, hitting $5.91. The company had a trading volume of 325,253 shares, compared to its average volume of 624,445. Voyager Therapeutics, Inc. has a 1-year low of $5.19 and a 1-year high of $11.72. The company has a market cap of $322.84 million, a PE ratio of 8.32 and a beta of 0.90. The business has a 50-day moving average of $6.39 and a 200-day moving average of $7.02.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the business posted ($0.59) EPS. Research analysts forecast that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on VYGR shares. Citigroup initiated coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price objective on the stock. Leerink Partners initiated coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. Wedbush began coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price objective for the company. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $17.00.

Institutional Investors Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Great Point Partners LLC acquired a new stake in Voyager Therapeutics during the second quarter worth about $12,668,000. FMR LLC grew its holdings in shares of Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares during the last quarter. Armistice Capital LLC raised its position in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the period. Verition Fund Management LLC bought a new stake in shares of Voyager Therapeutics in the 3rd quarter worth approximately $216,000. Finally, Erste Asset Management GmbH acquired a new position in Voyager Therapeutics during the 3rd quarter valued at approximately $6,192,000. 48.03% of the stock is owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.